
    
      Compare the clinical characteristics and post-surgical outcomes (overall survival)of
      pancreatic cancer patients of Ashkenazi descent with or without germline founder mutations in
      BRCA1 or BRCA2 .

      Compare the clinical characteristics and outcomes (time to progression) of breast cancer
      patients of Ashkenazi descent with or without germline founder mutations in BRCA1 or BRCA2
      receiving paclitaxel chemotherapy for metastatic disease.
    
  